LNTH · XBRL financial data

Lantheus Holdings financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LNTH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	339	425	935	1,296	1,534	1,542
Cost of goods and services sold	201	238	353	587	546	600
Gross profit	139	188	582	710	988	942
Research and development	33	45	312	78	168	177
General and administrative	69	150	134	125	194	275
Total operating expenses	143	—	—	—	—	—
Operating income (loss)	(4)	(61)	36	365	457	311
Interest income	0	0	3	20	37	—
Interest expense	9	8	7	20	20	20
Other income (expense)	2	(7)	(2)	66	37	31
Income tax expense (benefit)	2	(4)	(1)	84	119	80
Net income (loss)	(13)	(71)	28	327	312	234
Earnings per share, basic USD per share	(0.25)	(1.06)	0.41	4.79	4.52	3.46
Earnings per share, diluted USD per share	(0.25)	(1.06)	0.40	4.65	4.36	3.41
Weighted average shares, basic millions of shares	54	67	68	68	69	67
Weighted average shares, diluted millions of shares	54	67	71	70	72	68

Fiscal years (LNTH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	80	99	416	714	913	359
Accounts receivable	54	89	213	284	321	359
Inventory	36	35	35	64	68	65
Total current assets	184	236	678	1,086	1,327	900
Property and equipment, net	120	117	122	147	177	164
Right-of-use asset	18	9	19	45	36	31
Goodwill	59	61	61	61	61	240
Total assets	870	864	1,321	1,651	1,980	2,227
Accounts payable	16	21	21	41	35	43
Current portion of long-term debt	21	12	0	1	1	1
Total current liabilities	81	90	248	187	241	333
Long-term debt	198	163	558	—	—	—
Lease liability, non-current	18	17	25	54	53	50
Total liabilities	356	399	874	835	892	1,138
Retained earnings (accumulated deficit)	(150)	(221)	(193)	134	446	680
Total stockholders' equity	514	464	447	816	1,088	1,090
Total liabilities and equity	870	864	1,321	1,651	1,980	2,227
Common shares outstanding (cover page) millions of shares	67	68	68	69	68	65

Fiscal years (LNTH's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(13)	(71)	28	327	312	234
Stock-based compensation	14	16	29	51	76	86
Net cash from operating activities	16	54	282	305	545	390
Net cash from investing activities	(5)	4	(277)	6	(226)	(627)
Proceeds from issuing common stock	1	1	1	2	3	—
Share repurchases	0	0	75	0	100	300
Proceeds from long-term debt	0	0	558	0	0	—
Repayments of long-term debt	15	43	175	1	0	1
Net cash from financing activities	(22)	(39)	312	(13)	(119)	(317)
Net change in cash	(10)	18	317	298	199	(554)

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Lantheus Holdings	593	388	92*	65.3M	—	Q2 FY26 10-QJun 30, 2026
Adma Biologics	136	124	30*	224.0M	—	Q2 FY26 10-QJun 30, 2026
Axsome Therapeutics	314	260	(9.5)*	52.6M	14.7 quarters	Q3 FY26 10-QSep 30, 2026
Soleno Therapeutics	133	not reported	26	52.1M	—	Q1 FY26 10-QMar 31, 2026
Halozyme Therapeutics	163	481	241*	113.5M	—	Q2 FY26 10-QJun 30, 2026
Alkermes	631	480	93*	168.0M	—	Q3 FY26 10-QSep 30, 2026
Rhythm Pharmaceuticals	40	92	(3.1)*	69.3M	16.9 quarters	Q3 FY26 10-QSep 30, 2026
Vaxcyte	183	not reported	(232)*	148.8M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
PERRIGO	400	1,023	83*	138.8M	—	Q2 FY26 10-QJun 27, 2026

Not investment advice. Not affiliated with the U.S. SEC.